Economists Refute Relation Between Size of Cancer Drug Vials and Healthcare Costs
In a blogpost on Health Affairs, 2 economists have challenged the claim made by researchers that packaging expensive, patented chemotherapy drugs into multiple vial sizes could reduce wastage and in turn significantly reduce healthcare costs.
In a blogpost on Health Affairs, 2 economists have challenged the claim made by researchers that packaging expensive, patented chemotherapy drugs into multiple vial sizes could reduce wastage and in turn significantly reduce healthcare costs.
A
Based on their findings, the authors of the BMJ paper recommended distributing these drugs in multiple vial sizes and also refund the costs of the discarded drugs to private and federal health plans.
But Sherry Glied, PhD; and Bhaven Sampat, PhD, disagree with these claims, calling it a shortcut solution. In their
They also suggest that the analysis includes a significant pricing error. Patent monopolies mean manufacturers can seek the highest “willingness to pay” price for a drug—independent of vial size, but more driven by documented outcomes following treatment. “When the marginal cost of the drug material is high, that might mean shipping in multiple sizes of vials; when the marginal cost is low, as it is for most cancer drugs, it might be least costly to ship in a limited number of vial sizes and allow the excess drug material to be wasted,” the authors write in their blog.
Ultimately, variable vial sizes may only impact production costs for the manufacturers and may not even make a dent in the price that consumers and payers end up paying for the drug.
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Related Articles
- Promising Early Efgartigimod Response Data for Generalized Myasthenia Gravis
September 18th 2025
- Iron Dysregulation Linked to MS Progression, Review Finds
September 18th 2025
- Metabolic Issues More Common in Patients With HIV
September 18th 2025
- Barriers to Gender-Affirming Surgery Persist Despite High Satisfaction Rate
September 18th 2025